Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.

Transcription factors of the NF-kappaB/Rel family are critical for inducible expression of multiple genes involved in inflammatory responses. Sulfasalazine and its salicylate moiety 5-aminosalicylic acid are among the most effective agents for treating inflammatory bowel disease and rheumatoid arthritis. However, the mode of action of these drugs remains unclear. Here we provide evidence that the transcription factor NF-kappaB is a target of sulfasalazine-mediated immunosuppression. Treatment of SW620 colon cells with sulfasalazine inhibited TNFalpha-, LPS-, or phorbol ester- induced NF-kappaB activation. NF-kappaB-dependent transcription was inhibited by sulfasalazine at micro- to millimolar concentrations. In contrast, 5-aminosalicylic acid or sulfapyridine did not block NF-kappaB activation at all doses tested. TNFalpha-induced nuclear translocation of NF-kappaB was prevented by sulfasalazine through inhibition of IkappaBalpha degradation. When blocking proteasome-mediated degradation of IkappaBalpha, we could demonstrate that sulfasalazine interfered with IkappaBalpha phosphorylation, suggesting a direct effect on an IkappaBalpha kinase or on an upstream signal. Inhibition of NF-kappaB activation seems to be specific since other DNA-binding activities such as AP1 were not affected. These results demonstrate that sulfasalazine is a potent and specific inhibitor of NF-kappaB activation, and thus may explain some of the known biological properties of sulfasalazine.

[1]  M. Neurath,et al.  Local administration of antisense phosphorothiate olignucleotides to the p65 subunit of NF–κB abrogates established experimental colitis in mice , 1996, Nature Medicine.

[2]  F. Luscinskas,et al.  Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. , 1996, Journal of immunology.

[3]  O. Martínez-Maza,et al.  Differential regulation of IL-6 gene transcription and expression by IL-4 and IL-10 in human monocytic cell lines. , 1996, Journal of immunology.

[4]  P. Tassone,et al.  IL-10 inhibits nuclear factor-kappa B/Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes. , 1996, Journal of immunology.

[5]  S. Gerstberger,et al.  Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation , 1995, Science.

[6]  M. Karin,et al.  Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. , 1995, Science.

[7]  P. Cerutti,et al.  The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. , 1995, Chemistry & biology.

[8]  E. A. O'neill,et al.  The effect of sodium salicylate and aspirin on NF-kappa B. , 1995, Science.

[9]  A. Baldwin,et al.  Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. , 1995, Science.

[10]  H. Bird.  Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis? , 1995, British journal of rheumatology.

[11]  Betts,et al.  Structural and functional analysis of NF-kappa B. Determinants of DNA binding specificity and protein interaction. , 1994, The Journal of biological chemistry.

[12]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[13]  K. Schulze-Osthoff,et al.  Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Franzoso,et al.  Structure, regulation and function of NF-kappa B. , 1994, Annual review of cell biology.

[15]  M. Kagnoff,et al.  Colonic epithelial cell lines as a source of interleukin-8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide. , 1994, Immunology.

[16]  A. Goldberg,et al.  The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. , 1994, Cell.

[17]  M. Grisham.  Role of reactive oxygen metabolites in inflammatory bowel disease , 1993 .

[18]  A. Baldwin,et al.  Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation , 1993, Molecular and cellular biology.

[19]  G. May,et al.  Sulfasalazine Revisited , 1993, Annals of Internal Medicine.

[20]  G. Nabel,et al.  Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3) , 1993, Molecular and cellular biology.

[21]  T. Gaginella,et al.  Sulfasalazine. Multiplicity of action. , 1992, Digestive diseases and sciences.

[22]  M. Omary,et al.  Biochemical and morphological differentiation of the human colonic epithelial cell line SW620 in the presence of dimethylsulfoxide , 1992, Journal of cellular biochemistry.

[23]  P. Baeuerle.  Dithiocarbamates as Potent Inhibitors of Nuclear Factor KB Activation in Intact Cells By galf Schreck, Beate Meier,* Daniela N. M~innel,~ Wulf Dr6ge,~ , 1992 .

[24]  Gary J. Nabel,et al.  Cloning of an NF-κB subunit which stimulates HIV transcription in synergy with p65 , 1991, Nature.

[25]  P. Baeuerle,et al.  Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF‐kappa B transcription factor and HIV‐1. , 1991, The EMBO journal.

[26]  I. Yamamoto,et al.  Inhibition of proliferative responses and interleukin 2 productions by salazosulfapyridine and its metabolites. , 1990, Japanese journal of pharmacology.

[27]  G. Smedegård,et al.  Inhibitory effects of sulfasalazine and related compounds on superoxide production by human polymorphonuclear leukocytes. , 1989, Pharmacology & toxicology.

[28]  R. Macdermott,et al.  Inhibition of antibody secretion by 5-aminosalicylic acid. , 1989, Gastroenterology.

[29]  K. Grindulis,et al.  Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action? , 1988, British journal of rheumatology.

[30]  O. Aruoma,et al.  The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects? , 1987, Biochemical pharmacology.

[31]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[32]  A. Taggart,et al.  5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis? , 1986, Drugs.

[33]  D. Jewell,et al.  Inhibition of leucocyte motility by drugs used in ulcerative colitis. , 1981, Gut.

[34]  K Heinkel,et al.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. , 1980, The New England journal of medicine.

[35]  R. A. Murphy,et al.  Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: effects of sulfasalazine in vivo and in vitro. , 1978, Clinical and experimental immunology.

[36]  S. Truelove,et al.  AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE , 1977, The Lancet.

[37]  J. McManus,et al.  The metabolism of salicylazosulphapyridine in ulcerative colitis , 1973, Gut.

[38]  M. Peppercorn,et al.  Distribution studies of salicylazosulfapyridine and its metabolites. , 1973, Gastroenterology.

[39]  O. Bonnevie,et al.  The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year. , 1973, Scandinavian journal of gastroenterology.